Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604311 | 0.88 | ERN1 (0.41) | ERN1ESR1ESR2MIFTAAR1 | |
| Phloroglucinaldehyde SCHEMBL307321 | 0.83 | ERN1 (0.48) | ERN1CYP3A4MAPTMGAMGAA | |
| SCHEMBL3967319 | 0.82 | ERN1 (0.52) | ERN1CYP3A4MAPTCA12CA1 | |
| Phloroglucinaldehyde SCHEMBL9238987 | 0.80 | ERN1 (0.47) | ERN1CYP3A4MAPTMGAMGAA | |
| Phloroglucinaldehyde SCHEMBL19463561 | 0.80 | ERN1 (0.47) | ERN1CYP3A4MAPTMGAMGAA | |
| Phloroglucinaldehyde SCHEMBL28075548 | 0.80 | ERN1 (0.47) | ERN1CYP3A4MAPTMGAMGAA | |
| SCHEMBL11179328 | 0.78 | ERN1 (0.43) | ERN1CYP3A4MAPTCA1CA9 | |
| SCHEMBL16268831 | 0.78 | ERN1 (0.41) | ERN1CYP3A4MAPT | |
| SCHEMBL1459005 | 0.78 | HSD17B10 (0.41) | ERN1ESR1ESR2CYP3A4MAPT | |
| SCHEMBL12581672 | 0.78 | SELL (0.46) | ERN1CYP3A4MAPTGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4676919-A1 | MONOFLUORINATED COUMARIN FLUOROPHORES AND USES THEREOF | Ohio State Innovation Foundation (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024220708-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | GANDEEVA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024186721-A1 | MONOFLUORINATED COUMARIN FLUOROPHORES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-2354134-B1 | 2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR | ASTELLAS PHARMA INC (JP) | 2016-02-24 | — | — | EP | disclosed |
| CN-102239164-B | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC | 2013-10-30 | — | — | CN | disclosed |
| US-8343944-B2 | Trisubstituted boron-containing molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343944-B2 | Trisubstituted boron-containing molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343944-B2 | Trisubstituted boron-containing molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-6211234-B1 | BENZONITRILE COMPOUNDS WITH ETHER AND SULFIDE GROUPS WITH CARBOXY ACID | RHONE-POULENC RORER LIMITED (GB) | 2001-04-03 | — | — | US | disclosed |
| US-6124343-A | Substituted phenyl compounds with a substituent having a thienyl ring | RHONE-POULENC RORER LIMITED (GB) | 2000-09-26 | — | — | US | disclosed |
| EP-0805802-B1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE POULENC RORER LTD (GB) | 2000-08-16 | — | — | EP | disclosed |
| US-6048893-A | Substituted phenyl compounds with a substituent having A 1,3-benzodioxole ring | RHONE-POULENC RORER LIMITED (GB) | 2000-04-11 | — | — | US | disclosed |
| EP-0728128-B1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE POULENC RORER LTD (GB) | 1998-09-16 | — | — | EP | disclosed |
| CN-1178525-A | Substituted phenyl compounds as endothelin antagonists | RHONE POULEUC RORER LTD (GB) | 1998-04-08 | — | — | CN | disclosed |
| EP-0805802-A1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE-POULENC RORER LIMITED (GB) | 1997-11-12 | — | — | EP | disclosed |
| EP-0728128-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1996-08-28 | — | — | EP | disclosed |
| WO-1996022978-A1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE POULENC RORER LIMITED (GB) | 1996-08-01 | — | — | WO | disclosed |
| WO-1995013262-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | ERN1 1543/4885ESR1 522/4885ESR2 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.